ribosomal protein S14Genealiases: EMTB · S14 · uS11
Q-omics provides the consensus-scored RPS14 profile across patient tissues and cancer cell-line models. RPS14 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, RPS14 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, RPS14 protein abundance shows 25,203 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight LIHC, KIRC, and PDAC as cancer lineages where RPS14 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPS14 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPS14 survival associations across molecular data types. RPS14 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (1) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPS14 RNA expression–survival associations across cancer types. High RPS14 expression shows unfavorable associations in LIHC and KIRP, but favorable associations in UVM, THYM, LGG and BRCA. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for RPS14 RNA expression.
This table summarizes RPS14 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for RPS14. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPS14 shows lower tumor expression in BRCA and higher tumor expression in KIRC, COAD, LIHC, KIRP and CHOL. The KIRC box plot shows higher RPS14 RNA expression in tumor versus normal tissue (log2 FC = +1.141, t-test p < 0.001).
This table shows molecular features associated with RPS14 in patient tissues and cancer cell lines. In patient samples, RPS14 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, RPS14 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BLOOD_Leukemia.
